Cardiol Therapeutics (CRDL) Shares Outstanding (2020 - 2026)

Cardiol Therapeutics (CRDL) has 7 years of Shares Outstanding (Entity) data on file, last reported at $109.0 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 31.93% year-over-year to $109.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $109.0 million (up 31.93% YoY) and the FY2025 annual result came in at $87.0 million, up 21.55% from the prior year.
• Shares Outstanding (Entity) improved to $109.0 million in Q1 2026, from $87.0 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $109.0 million in Q1 2026 to a low of $61.9 million in Q1 2022.
• A 5-year average of $72.3 million and a median of $67.3 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) jumped 78.95% — and 2023, when it advanced 3.13%.
• Tracing CRDL's Shares Outstanding (Entity) over 5 years: stood at $62.5 million in 2022, then grew by 3.13% to $64.5 million in 2023, then grew by 11.02% to $71.6 million in 2024, then grew by 21.55% to $87.0 million in 2025, then advanced by 25.29% to $109.0 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $109.0 million (Q1 2026), $87.0 million (Q4 2025), and $84.7 million (Q3 2025), per Business Quant data.